Inversago Pharma Doses First Patient in Phase II Trial of INV-202, an Oral, Peripherally-acting CB1 Inverse Agonist, in Patients with Diabetic Kidney Disease

By
lbeveridge
-
0
189
Inversago Pharma, Inc. announced that the first patient has been dosed with INV-202 in a Phase II clinical trial in subjects with diabetic kidney disease.
[Inversago Pharma, Inc. (BusinessWire, Inc.)]
Press Release